Repligen and Univercells Technologies have partnered to embed the MAVEN real-time glucose control platform in Univercells’ scale-X bioreactors. This innovation enables continuous measurement of glucose and lactate concentrations during viral vector and vaccine manufacturing without removing media samples. The collaboration aims to optimize cell culture conditions through higher frequency and automation of metabolic data collection, enhancing process analytical technology (PAT) in advanced therapy production.